2 Beaten-Down Stocks That Still Aren't Worth Buying
As conventional investment wisdom has it, it's best to buy low and sell high. However, that only works when you have solid reasons to believe a company's shares will bounce back meaningfully after a decline.
Some corporations have uncertain prospects that make their shares not worth buying, even on the dip. Let's look at two companies that fit this description: (NASDAQ: NVAX) and Sage Therapeutics (NASDAQ: SAGE). Here's why if you're considering opening positions in either biotech stock, you might save yourself the trouble.
Novavax is suffering the same fate as some other coronavirus vaccine makers that enjoyed impressive runs. With the COVID-19 pandemic receding, the need for vaccines isn't as urgent as it once was. Of course, COVID is likely here to stay. A recent surge in confirmed cases highlights that fact quite well.
Source Fool.com
Novavax Inc. Aktie
Leichtes Buy-Überwiegen bei Novavax Inc. im Vergleich zu Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Novavax Inc. von 22 € würde den aktuellen Kurs von 10.55 € mehr als verdoppeln.
